Natera president sells 3,000 shares under 10b5-1 plan

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported selling 3,000 shares of Natera common stock in open-market transactions on July 1, 2026.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported selling 3,000 shares of Natera common stock in open-market transactions on July 1, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating the trades were scheduled in advance. Reported weighted average prices were about $274.06, $272.99, and $267.19 per share, with actual trade prices ranging between $267.05 and $273.00. Moshkevich continues to hold a direct equity stake in Natera after these sales.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 3 txns

Insider Moshkevich Solomon

Role PRESIDENT, CLINICALDIAGNOSTICS

Sold 3,000 shs ($819K)

Type	Security	Shares	Price	Value
Sale	Common Stock	100	$267.185	$27K
Sale	Common Stock	2,600	$272.99	$710K
Sale	Common Stock	300	$274.06	$82K

Holdings After Transaction: Common Stock — 134,643 shares (Direct)

Footnotes (3)

F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.05 to $267.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.74 to $273.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 3,000 shares Weighted average price 1: $274.06/share Weighted average price 2: $272.99/share +4 more

7 metrics

Shares sold 3,000 shares Total Natera common shares sold by Solomon Moshkevich on July 1, 2026

Weighted average price 1 $274.06/share Weighted average sale price for 300 shares of common stock

Weighted average price 2 $272.99/share Weighted average sale price for 2,600 shares of common stock

Weighted average price 3 $267.185/share Weighted average sale price for 100 shares of common stock

Price range lower band $267.05–$267.30/share Range of individual trade prices for one sale tranche

Price range upper band $272.74–$273.00/share Range of individual trade prices for another sale tranche

10b5-1 plan adoption date November 26, 2024 Date Solomon Moshkevich adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Natera (NTRA) report for Solomon Moshkevich?

Natera reported that president of clinical diagnostics Solomon Moshkevich sold 3,000 shares of common stock in open-market transactions on July 1, 2026. The transactions were routine sales executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024.

At what prices did Natera (NTRA) insider Solomon Moshkevich sell shares?

The reported weighted average prices were $274.06, $272.99, and $267.19 per share for the 3,000 shares sold. Footnotes state the actual trades occurred in multiple lots between $267.05–$267.30 and $272.74–$273.00 per share, inclusive, on July 1, 2026.

How many Natera (NTRA) shares did Solomon Moshkevich sell in this Form 4?

Solomon Moshkevich sold a total of 3,000 shares of Natera common stock across three open-market transactions. Each transaction involved 300, 2,600, and 100 shares respectively, all on July 1, 2026, as disclosed in the Form 4 filing.

Was the Natera (NTRA) insider sale by Solomon Moshkevich under a Rule 10b5-1 plan?

Yes. The filing states the sale of shares was effected under a Rule 10b5-1 trading plan adopted on November 26, 2024. Such plans pre-schedule trades, indicating these transactions were planned in advance rather than discretionary timing decisions.

What type of transaction did Natera (NTRA) report for Solomon Moshkevich?

The Form 4 reports open-market sales of Natera common stock by Solomon Moshkevich, coded as “S” transactions. These are non-derivative stock sales, not option exercises or tax withholdings, and reflect direct ownership being reduced by 3,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/06/2026 - 09:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last)

(First)

(Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN

TEXAS

78753

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		S		100⁽¹⁾	D	$267.185⁽²⁾	137,543	D
Common Stock	07/01/2026		S		2,600⁽¹⁾	D	$272.99⁽³⁾	134,943	D
Common Stock	07/01/2026		S		300⁽¹⁾	D	$274.06	134,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.05 to $267.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.74 to $273.00 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Tami Chen, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Natera president sells 3,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Positive

Negative